Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations

Scientific Reports - Tập 8 Số 1
Julia A. Yaglom1, Yongmei Wang2, Amy Li1, Zhenghu Li3, Stefano Monti1, Ilya Alexandrov4, Xiongbin Lu3, Michael Y. Sherman5
1Boston University School of Medicine, Boston, United States
2Center of Diagnosis and Treatment of Breast Disease, The Affiliated Hospital of Qingdao University, Qingdao, China
3MD Anderson Cancer Center, Houston, USA
4ActivSignal, Watertown, MA, USA
5Department Molecular Biology Ariel University, Ariel, Israel

Tóm tắt

AbstractHsp70 is a promising anti-cancer target. Our JG-98 series of Hsp70 inhibitors show anti-cancer activities affecting both cancer cells and tumor-associated macrophages. They disrupt Hsp70 interaction with a co-chaperone Bag3 and affect signaling pathways important for cancer development. Due to a prior report that depletion of Hsp70 causes similar responses as depletion of Hsp90, interest to Hsp70 inhibitors as drug prototypes is hampered by potential similarity of their effects to effects of Hsp90 inhibitors. Here, using the Connectivity Map platform we demonstrate that physiological effects of JG-98 are dissimilar from effects of Hsp90 inhibitors, thus justifying development of these compounds. Using gene expression and ActivSignal IPAD platform, we identified pathways modulated by JG-98. Some of these pathways were affected by JG-98 in Bag3-dependent (e.g. ERK) and some in Bag3-independent manner (e.g. Akt or c-myc), indicating multiple effects of Hsp70 inhibition. Further, we identified genes that modulate cellular responses to JG-98, developed approaches to predict potent combinations of JG-98 with known drugs, and demonstrated that inhibitors of proteasome, RNApol, Akt and RTK synergize with JG-98. Overall, here we established unique effects of novel Hsp70 inhibitors on cancer cell physiology, and predicted potential drug combinations for pre-clinical development.

Từ khóa


Tài liệu tham khảo

Lindquist, S. & Craig, E. A. The heat-shock proteins. Annual Review of Genetics. 22, 631–77 (1988).

Michels, A. A. et al. Hsp70 and Hsp40 chaperone activities in the cytoplasm and the nucleus of mammalian cells. Journal of Biological Chemistry. 272, 33283–33289 (1997).

Stege, G. J. et al. On the role of hsp72 in heat-induced intranuclear protein aggregation. International Journal of Hyperthermia. 10, 659–74 (1994).

Jaattela, M. Escaping cell death: Survival proteins in cancer [Review]. Experimental Cell Research. 248, 30–43 (1999).

Jolly, C. & Morimoto, R. I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 92, 1564–72 (2000).

Mosser, D. D. & Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene. 23, 2907–18 (2004).

Calderwood, S. K., Khaleque, M. A., Sawyer, D. B. & Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 31, 164–72 (2006).

Ciocca, D. R. & Calderwood, S. K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 10, 86–103 (2005).

Meng, L. et al. Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene. 30, 2836–45 (2011).

Gong, J. et al. Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis. Oncogene (2015).

Tao, Y. et al. Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model. Carcinogenesis. 37, 731–9 (2016).

Hunt, C. R. et al. Genomic instability and enhanced radiosensitivity in Hsp70.1- and Hsp70.3-deficient mice. Mol Cell Biol. 24, 899–911 (2004).

Wang, Z. et al. Induction of heat shock protein 70 inhibits ischemic renal injury. Kidney Int. 79, 861–70 (2011).

McConnell, K. W. et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. J Immunol. 186, 3718–25 (2011).

Rerole, A. L. et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 71, 484–95 (2011).

Leu, J. I. et al. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell. 36, 15–27 (2009).

Chang, L. et al. Chemical screens against a reconstituted multiprotein complex: myricetin blocks DnaJ regulation of DnaK through an allosteric mechanism. Chem Biol. 18, 210–21 (2011).

Huryn, D. M. et al. Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators. Proc Natl Acad Sci USA 108, 6757–62 (2011).

Braunstein, M. J. et al. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011, 232037 (2011).

Massey, A. J. et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 66, 535–45 (2010).

Rodina, A. et al. Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Chem Biol. 20, 1469–80 (2013).

Koren, J. III et al. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PloS one. 7, e35566 (2012).

Colvin, T. A. et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res. 74, 4731–40 (2014).

Li, X. et al. Validation of the hsp70-bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 14, 642–8 (2015).

Gabai, V. L. et al. Anticancer Effects of Targeting Hsp70 in Tumor Stromal Cells. Cancer research. 76, 5926–5932 (2016).

Masarwa, M., Donin, N., Ziporen, L. & Fishelson, Z. Silencing of the Mitochondrial Hsp70 Mortalin as an Adjuvant Cancer Therapy. Annals of Oncology. 20, 29–29 (2009).

Na, Y. et al. Stress Chaperone Mortalin Contributes to Epithelial-to-Mesenchymal Transition and Cancer Metastasis. Cancer Research. 76, 2754–2765 (2016).

Lee, A. S. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Research. 67, 3496–3499 (2007).

Li, J. Z. & Lee, A. S. Stress induction of GRP78/BiP and its role in cancer. Current Molecular Medicine. 6, 45–54 (2006).

Powers, M. V., Clarke, P. A. & Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer cell. 14, 250–62 (2008).

Yaglom, J., O’Callaghan-Sunol, C., Gabai, V. & Sherman, M. Y. Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72. Mol Cell Biol. 23, 3813–24 (2003).

Falco, A. et al. BAG3 controls angiogenesis through regulation of ERK phosphorylation. Oncogene. 31, 5153–61 (2012).

Meriin, A. B. et al. Protein damaging stresses activate JNK via inhibition of its phosphatase: A novel pathway controlled by Hsp72. Mol.Cell. Biol. 19, 2547–2555 (1999).

Li, X. et al. Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett. 4 (2013).

Casson, J., McKenna, M. & High, S. On the road to nowhere: cross-talk between post-translational protein targeting and cytosolic quality control. Biochemical Society transactions. 44, 796–801 (2016).

Behl, C. Breaking BAG: The Co-Chaperone BAG3 in Health and Disease. Trends in pharmacological sciences. 37, 672–88 (2016).

Petrocca, F. et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer cell. 24, 182–96 (2013).

Liu, Y. et al. TP53 loss creates therapeutic vulnerability incolorectal cancer. Nature. 520, 697–701 (2015).

Liu, Y., Wang, L. & Lu, X. A new way to target p53-defective colorectal cancer. Future oncology (London, England). 11, 3101–4 (2015).

Assimon, V. A., Gillies, A. T., Rauch, J. N. & Gestwicki, J. E. Hsp70 protein complexes as drug targets. Curr Pharm Des. 19, 404–17 (2013).

Wang, A. M. et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol. 9, 112–8 (2013).

Yaglom, J. A., Gabai, V. L. & Sherman, M. Y. High levels of heat shock protein Hsp72 in cancer cells suppress default senescence pathways. Cancer Res. 67, 2373–81 (2007).

Thông tin
Thông tin xuất bản

Scientific Reports

Tập 8 Số 1

Thông tin tác giả